

Leukos Biotech

Josep Carreras Foundation Delegate Committee

9 March 2017

Contents

Review of last year's achievements

■ Scientific/Development

APOMORPHINE

- Reformulation
- Intellectual Property
- Clinical trial

■ Financial

PRIVATE FUNDING

- Inveready

PUBLIC FUNDING


- Awarded
- Requested

■ Other

INICIA PRIZE

- Scientific/Development

APOMORPHINE: Reformulation



Collaboration with Enantia (Bcn) to obtain a new pharmaceutical method for sustained release



- Scientific/Development

APOMORPHINE: Intellectual Property – National phase

Country	National Phase Entry	Application Number
Australia	24/Nov/2016	2015279105
Brazil	15/Dec/2016	BR 112016029562-5
Canada	21/Dec/2016	2953272
China	21/Dec/2016	2015800336621
India	2/Dec/2016	201617041183
Israel	15/Dec/2016	249579
Japan	21/Dec/2016	JP2016-575341
Korea	20/Dec/2016	10-2016-7035701
Mexico	19/Dec/2016	MX/a/2016/016994
Russian Federation	27/Jan/2017	2016147748
South Africa	4/Jan/2017	2017/00080
USA	23/Dec/2016	15322012
Europe	27/Jan/2017	EP15731945.0

- Scientific/Development

APOMORPHINE: Intellectual Property – New patent

New patent covering use of Apomorphine in combination with standard AML treatment.



MINISTERIO
DE INDUSTRIA, ENERGIA
Y TURISMO




Oficina Española
de Patentes y Marcas

Acknowledgement of receipt

We hereby acknowledge receipt of your request for grant of a European patent as follows:

Submission number	300219882
Application number	EP17382015.0
File No. to be used for priority declarations	EP17382015
Date of receipt	16 January 2017
Your reference	P13937EP00
Applicant	LEUKOS BIOTECH, S.L.
Country	ES
Title	COMBINATION THERAPY FOR TREATING CANCER



- Scientific/Development

APOMORPHINE: Clinical trial– 4th quarter 2017

CRO: Dr. Jordi Roma

Lead researcher: Dr. Jordi Esteve

Recerca Clínica | *Clinical Research Experts*

CLÍNIC
BARCELONA
Hospital Universitari



60 patients

Patients diagnosed with AML for first time.
Candidates for intensive chemotherapy (>60 years of age).
Not previously treated with hypomethylants.

Treatment: Apomorphine + Decitabine / Decitabine

40 patients

Patients with relapsed or refractory AML.
No other effective treatment available.

Treatment: Apomorphine

Financial

PRIVATE FUNDING

- Inveready

July 2016 – Partner agreement

Valuation Leukos: €850,000

1st Phase: **€300,000** – July 2016, Inveready share 26%

2nd Phase: **€500,000** – Clinical trial approved by AEMPS (Dec. 2017), Inveready share 48%

Partner	Shares	Capital	%	Shares	Capital	%
Dr.Risueño	240	2,400	13.57	240	2,400	9.46
IJC	200	2,000	11.31	200	2,000	7.88
FJC	700	7,000	39.59	700	7,000	27.59
E. Llaudet	167	1,670	9.45	167	1,670	6.58
Inveready	461	4,610	26.07	1230	7,690	48.48
		17,680			20,760	

TOTAL INVEREADY CONTRIBUTION (2 PHASES) : €800,000

- Financial

PUBLIC FUNDING

- ACCIÓ (Generalitat de Catalunya) – AWARDED
 - Subsidy: **€50,000**
- RETOS 2016 (Ministry of Economy, Industry and Competitiveness) – AWARDED
 - Loan (LEUKOS): **€340,000** (0.06% interest, 3 years deferral, 7 years repayment)
 - Subsidy (IJC): **€180,000**
- CaixaImpulse (La Caixa) – AWARDED
 - Dr. Ruth M. Risueño (IJC): subsidy **€70,000** for valuation and IP transfer
- Tax breaks- HIGEA / Inveready
 - First payment received: €48,000
 - Total 2016-2019: **€700,000**
- NEOTEC 2016 (CDTI) – AWARDED
 - Subsidy: **€212,000**

TOTAL (Leukos + IJC): €1.5M

- Financial

PUBLIC FUNDING

- EU H2020 SME Instrument Phase 2 – Requested
 - Subsidy: €1.5M
 - Decision: June 2017
- EU ERC Consolidator Grant – Requested
- Subsidy Dr. Ruth M. Risueño (IJC): €1M
 - Subsidy Leukos: €0.5M
 - Decision: November 2017

TOTAL Requested (Leukos): €2M

- Other

2. INICIA PRIZE

Prize for the best start-up of 2016, awarded by *EL PERIODICO* and sponsored by BANC SABADELL

